Reports Q1 revenue $2.15B, consensus $2.16B. “We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA. Furthermore, all our business segments posted year-over-year revenue growth on both a reported and organic basis. I’m very proud of what our team has accomplished and we remain focused on continuing our momentum by advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth,” said Thomas J. Appio, Chief Executive Officer, Bausch Health. “We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb. We will continue to focus on the foundation we set across the enterprise to deliver results and improve the health of patients worldwide.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Reports Growth and Milestones
- Bausch Health price target raised to $9 from $7 at Piper Sandler
- Bausch Health price target lowered to $11 from $12 at RBC Capital
- Bausch Health put volume heavy and directionally bearish
- Jefferies healthcare analyst holds an analyst/industry conference call